A Multicentre, Open-label Phase II Study of Nab-paclitaxel in Combination With Gemcitabine + Cisplatin as First Line Treatment in Patients With Unresectable Biliary Tract Cancer
There is increasing evidence that there is a large degree of pathologic homology between the
pancreas and biliary tract. Indeed, the biliary tract has been referred to as "an incomplete
pancreas" and embryologically the two originate from the same structure. It is thus
plausible that oncogenesis in the pancreas and biliary tract are related and that pancreas
and biliary cancers have reciprocal effective treatment strategies.
To date, the only chemotherapeutic agents effective in advanced biliary tract tumours is the
combination of gemcitabine and cisplatin. Known and approved therapies for advanced pancreas
cancer include single agent gemcitabine, the four drug combination of FOLFIRINOX
(5-fluorouracil, leucovorin, oxaliplatin, and irinotecan), the questionable limited benefit
of inhibiting the epidermal growth factor receptor pathway, and most recently the
combination of gemcitabine and nab-paclitaxel.
Based on promising results in pancreas cancer, investigators hypothesize nab-paclitaxel in
combination with gemcitabine + cisplatin will be an effective cytotoxic combination in BTC
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society